title: Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices.
abstract: An HMG-CoA reductase inhibition assay was developed and validated for quantitation of atorvastatin in human, dog, rat, and mouse plasma. Atorvastatin was isolated from plasma by protein precipitation. Rat-liver microsomes were used to provide the reductase enzyme. The method was validated by assaying calibration standards and quality controls in triplicate on each of the 3 days. A customized computer program was used for data calculation. Quantitation of the assay ranged from 0.36 to 16 ng/ml of atorvastatin in different plasma matrices. Assay precision and accuracy, based on the coefficient of variation and percent relative error, respectively, of quality controls were 10.4% to 14.5% and within +/- 6.25% in human; 4.89% to 10.6% (+/- 8.13%) in dog; 2.68% to 8.62% (+/- 5.00%) in rat; and 3.68% to 8.96% (+/- 5.38%) in mouse plasma. The method has been applied to pharmacokinetic studies of atorvastatin in human and toxicokinetic studies in dog, rat, and mouse after atorvastatin administration. Atorvastatin equivalent concentrations in a set of plasma samples from subjects receiving single and multiple doses of atorvastatin were determined by validated HMG-CoA reductase inhibition assays at four different laboratories. Results were compared using linear regression and concordance correlation statistical procedures. Good agreements among these data indicated that results from different laboratories with the same validated method can be used interchangeably.
authors.affiliation: Pharmacokinetics/Drug Metabolism Department, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
authors.forename: Y Y
authors.initials: YY
authors.lastname: Shum
authors.forename: N
authors.initials: N
authors.lastname: Huang
authors.forename: G
authors.initials: G
authors.lastname: Walter
authors.forename: A
authors.initials: A
authors.lastname: Black
authors.forename: C
authors.initials: C
authors.lastname: Sekerke
authors.forename: T
authors.initials: T
authors.lastname: Chang
authors.forename: L R
authors.initials: LR
authors.lastname: Whitfield
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000097:blood*; D000069059:Atorvastatin; D001681:Biological Assay / Q000379:methods*; D008078:Cholesterol, LDL / Q000187:drug effects; D004285:Dogs; D006538:Heptanoic Acids / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000097:blood*; D007753:Laboratories; D016014:Linear Models; D051379:Mice; D011758:Pyrroles / Q000097:blood*; D051381:Rats
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin